Published in final edited form as:

Clin Sci (Lond). 2014 August ; 127(4): 209–216. doi:10.1042/CS20140070.

New frontiers in obstructive sleep apnoea

Najib T. AYAS^{*}, Allen A. J. HIRSCH^{*}, Ismail LAHER[†], T. Douglas BRADLEY^{‡,§}, Atul MALHOTRA^{||}, Vsevolod Y. POLOTSKY[¶], and Esra TASALI^{**}

^{*}Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada

[†]Department of Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada

[‡]Division of Respiriology, Centre for Sleep Medicine and Circadian Biology, University of Toronto, Toronto, Canada

[§]Sleep Research Laboratory of the Toronto Rehabilitation Institute, University Health Network Toronto, Toronto, Canada

^{||}Pulmonary and Critical Care Medicine, Faculty of Medicine, University of California San Diego, San Diego, U.S.A

[¶]Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, U.S.A

^{**}Section of Pulmonary & Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, U.S.A

Abstract

OSA (obstructive sleep apnoea), the most common respiratory disorder of sleep, is caused by the loss of upper airway dilating muscle activity during sleep superimposed on a narrow upper airway. This results in recurrent nocturnal asphyxia. Termination of these events usually requires arousal from sleep and results in sleep fragmentation and hypoxaemia, which leads to poor quality sleep, excessive daytime sleepiness, reduced quality of life and numerous other serious health consequences. Furthermore, patients with untreated sleep apnoea are at an increased risk of hypertension, stroke, heart failure and atrial fibrillation. Although there are many predisposing risk factors for OSA, including male gender, endocrine disorders, use of muscle relaxants, smoking, fluid retention and increased age, the strongest risk factor is obesity. The aim of the present review is to focus on three cutting-edge topics with respect to OSA. The section on animal models covers various strategies used to simulate the physiology or the effects of OSA in animals, and how these have helped to understand some of the underlying mechanisms of OSA. The section on diabetes discusses current evidence in both humans and animal models demonstrating that intermittent hypoxia and sleep fragmentation has a negative impact on glucose tolerance. Finally, the section on cardiovascular biomarkers reviews the evidence supporting the use of these biomarkers to both measure some of the negative consequences of OSA, as well as the potential benefits of OSA therapies.

Keywords

animal model; biomarker; cardiovascular disease; diabetes; obesity; obstructive sleep apnoea (OSA)

INTRODUCTION

OSA (obstructive sleep apnoea) is by far the most common respiratory disorder of sleep. OSA is caused by the loss of upper airway dilating muscle activity during sleep that is superimposed on a narrow upper airway, resulting in recurrent nocturnal asphyxia [1]. Termination of these events usually requires arousal from sleep to re-establish upper airway tone, eliminate obstruction and allow ventilation to resume. This sleep fragmentation and hypoxaemia lead to poor quality sleep, excessive daytime sleepiness, reduced vigilance, accidents, neurocognitive dysfunction, decreased work productivity, and reduced quality of life [2]. Furthermore, patients with untreated sleep apnoea are at increased risks of hypertension, stroke, heart failure and atrial fibrillation (Figure 1) [3].

There are many predisposing risk factors for OSA, including male gender, endocrine disorders (e.g. hypothyroidism and acromegaly), use of muscle relaxants, smoking, fluid retention and increased age [4]. However, the strongest risk factor is obesity, particularly central obesity. Fat deposition around the upper airway narrows it and predisposes it to collapse. Furthermore, obesity reduces lung volumes, which also destabilizes the upper airway by reducing the tethering effect of higher lung volume. The links between obesity and OSA are of particular concern given the increasing rates of obesity in the developed world. The prevalence of OSA in obese adults (aged 30 to 69 years) ranges from 11 to 46 % in women and 33 to 77 % in men [5,6]. Weight gain is also a strong predictor of incident OSA [7].

OSA is diagnosed by sleep testing, which usually consists of an attended overnight sleep study (polysomnogram) in a sleep laboratory or unattended overnight cardiopulmonary monitoring in the patient's home. Disease severity is classified according to the AHI (apnoea/hypopnoea index: the number of times the patient stops or decreases breathing per h of sleep). It is agreed by consensus that an AHI of <5 events/h of sleep is considered normal, between 5 and 15 is considered mild, between 15 and 30 is considered moderate and >30 is considered severe disease [8].

Although common, OSA is under-diagnosed. In a random population based sample of 602 individuals aged 30 to 60 years, an AHI of ≥ 5 was found in 24 % of men and 9 % of women [9]. Moderate-to-severe disease (AHI ≥ 15) occurred in 9 % of males and 4 % of females. It is estimated that approximately 90 % of women and 80 % of men with moderate-to-severe OSA have not been clinically diagnosed [10].

Nasal CPAP (continuous positive airway pressure) therapy is considered first-line treatment for moderate-to-severe OSA [11]. By establishing a positive transmural pressure in the pharynx during sleep, CPAP prevents the upper airway from collapsing. CPAP reduces the severity of sleep fragmentation and improves nocturnal oxygenation, thereby improving

daytime sleepiness, quality of life and neurocognitive function [12]. One of the major impediments to CPAP effectiveness is adherence (ranging from 50 to 75 %) [13]. It is well established that CPAP improves vigilance, and accumulating data suggest that CPAP improves a variety of other outcomes such as motor vehicle crashes and cardiovascular events. Other therapies for sleep apnoea include dental appliances, weight loss, upper airway surgery, nasal valves and upper airway electrical stimulation.

In the present review, we will focus on three cutting edge topics with respect to OSA: animal models of OSA, diabetes and OSA, and cardiovascular biomarkers and OSA.

ANIMAL MODELS OF OSA

In this section, we review the various strategies investigators have used to simulate the physiology or the effects of OSA in animals, and how these have helped to understand some of the underlying mechanisms of OSA.

Animals with spontaneous OSA

One naturally occurring animal model of spontaneous OSA is the English bulldog, a canine breed with an enlarged soft palate and narrow oropharynx. These animals can have central and obstructive apnoea with oxyhaemoglobin desaturation to levels below 90 % during REM (rapid-eye-movement) sleep [14,15]. This model has been used predominantly to study upper airway anatomy and physiology [15–17], including testing of the impact of pharmacological treatments such as serotonergic medication [19,20].

Several rodent models of upper airway obstruction during sleep have been identified recently [21]. The NZO (New Zealand obese) mouse is a model of polygenic obesity and the metabolic syndrome exhibiting leptin resistance [22]. Similar to OSA patients, NZO mice have an increased volume of pharyngeal soft tissue structures and fat deposition in the tongue [16,23–25]. These mice also suffer from inspiratory flow limitation and apnoeas. In addition, Polotsky et al. [26] measured upper airway collapsibility in genetically obese leptin-deficient (*ob/ob*) dietary obese and lean mice. Increased upper airway collapsibility occurred in both genetic and dietary obese mice [20]. These novel rodent models of sleep apnoea will provide new insights into the pathogenesis and pharmacotherapy of OSA.

Airway occlusion

Researchers have also simulated OSA with induced airway obstruction in animals. Examples include sedated and intubated pigs, where obstructive apnoeas were induced by recurrent endotracheal occlusions that allowed for the assessment of acute haemodynamic and autonomic nervous system responses [27], and a rodent model of upper airway occlusion that has also been developed [28]. Changes in neck flexion and body position of cats to cause airway obstruction during sleep have been reported [29].

In a sophisticated model using tracheostomized dogs, sleep state was continuously monitored using electroencephalography. A computer would generate periods of sleep-induced airway obstruction using a remote control signal closing a valve in the tracheostomy [30]. Upon arousal from sleep, the valve would be opened and the airway obstruction

released. This model was used to study sleep architecture, blood pressure and cardiac responses to apnoea [24,25,31]; however, the model is labour intensive with a low throughput making them challenging to use in studying OSA complications. Nevertheless, it is the animal model that most closely mimics the effects of human OSA yet developed because it not only induces apnoea, intermittent hypoxia and arousals from sleep, but it also induces marked negative intrathoracic pressure swings during obstructive apnoeas similar in magnitude to those that occur in humans. Using this model, it was shown that exposure of these dogs to OSA for several weeks caused daytime hypertension [26] and left ventricular systolic dysfunction [28].

Intermittent hypoxia

Today, the most commonly used rodent model of OSA is induction of intermittent hypoxia/re-oxygenation by rapid delivery of a hypoxic gas mixture to an airtight chamber, followed by flushing of the chamber with room air (e.g. 30 s of hypoxia alternating with 30 s of normoxia). Some models have tried to coincide delivery of hypoxic gases with the onset of sleep and removal when arousal occurs [32]; this approach is complex and labour intensive. Therefore the majority of studies have utilized models that are not strictly dependent on the timing of sleep and arousal. That is, rodents are exposed to periods of hypoxia of a fixed duration throughout the light phase (when they are usually asleep) and maintain normoxia during the dark phase when they are usually awake. Of note, studies using electroencephalography show that rodents exposed to this schedule of intermittent hypoxia also suffer from sleep fragmentation, abnormal sleep architecture, cognitive dysfunction and hypersomnolence [33,34].

It must be kept in mind that intermittent hypoxia does not reproduce all the physiological effects of OSA. That is, OSA is usually characterized by extreme swings in intrathoracic pressure due to effort against a closed airway and hypercapnia due to a reduction in ventilation; these would not be present in this model. Indeed, rodents are hypocapnic under conditions of hypoxia [35]. Furthermore, the degree of hypoxaemia is quite severe, to an extent not experienced by the vast majority of human patients with OSA [36]. Nevertheless, given that hypoxia/re-oxygenation is a key physiological feature of OSA and rodents exposed to intermittent hypoxia appear to suffer from many of the cardiovascular sequelae observed in patients with OSA (including hypertension, endothelial dysfunction, metabolic disorders and atherosclerosis) [37–40], this model is useful in potentially elucidating mechanisms of metabolic and cardiovascular effects of OSA.

Fletcher et al. [41] showed that rats exposed to intermittent hypoxia for 3 weeks developed hypertension. Furthermore, carotid body denervation attenuated the hypertensive response, demonstrating that carotid body stimulation and increased sympathetic output [42] were mechanisms of this effect. It was later established that intermittent hypoxia activates the carotid body via oxidative stress mechanisms, and that induction of HIF (hypoxia-inducible factor)-1 α and inhibition of HIF-2 α were involved [43].

Intermittent hypoxia induces metabolic complications, including dyslipidaemia, insulin resistance and glucose intolerance, and this effect is augmented by obesity [44]. Although

the molecular mechanisms of this interaction are not entirely clear, hypoxia of liver and adipose tissue probably play major roles [45,46].

One of the functions of the vascular endothelium is to regulate smooth muscle tone in arteries and arterioles. Endothelial function is assessed by measuring the degree of vasodilation in response to various stimuli (e.g. acetylcholine and transient forearm occlusion) and dysfunction is a precursor of atherosclerotic and other vascular diseases. Rats and mice exposed to intermittent hypoxia develop endothelial dysfunction [47,48]. Interestingly, treatment with allopurinol (a xanthine oxidase inhibitor) improved cardiac function in the setting of intermittent hypoxia, suggesting that free radical generation probably plays a role in mediating the vascular effects of intermittent hypoxia [49]. Furthermore, Savransky et al. [40] reported that 12 weeks of intermittent hypoxia in mice fed on a high-cholesterol diet resulted in atherosclerotic lesions of the aorta, which were absent in mice not exposed to intermittent hypoxia. In mice fed on a normal diet, there was no significant atherosclerosis, suggesting a potential modulating effect of diet on the vascular impacts of OSA [38].

In summary, rodent models of intermittent hypoxia mimicking oxyhaemoglobin desaturations in human OSA have been developed and used to study the mechanisms of cardiovascular and metabolic dysfunction.

OSA AND DIABETES

Diabetes is a chronic illness that is increasing in prevalence. Mechanistic studies in humans and animal models have demonstrated that intermittent hypoxia and sleep fragmentation can have a negative impact on glucose tolerance [50–52]. There is substantial evidence from population- based and clinical studies that associates OSA with metabolic derangements [53,54].

Multiple studies have assessed the prevalence and incidence of diabetes in patients with OSA [55–60]. Cross-sectional analyses indicate a significantly higher prevalence of diabetes in patients with OSA compared with those without OSA, with rates ranging from 15 to 30 % depending on the study population, the definition of OSA severity and the methods used to diagnose diabetes [55–57]. Several studies have also reported a significant association between increasing severity of OSA and the prevalence of diabetes [56,58].

A number of prospective studies have also examined the incidence of diabetes in patients with OSA. Overall, the results are somewhat mixed in terms of demonstrating an independent effect of OSA on incident diabetes. In the Wisconsin Sleep Cohort [56], OSA was associated with a higher risk for incident diabetes over a 4-year period, but this association was no longer significant after adjusting for confounders such as age, sex and body habitus. In the Busselton Health Study [58], there was a significant independent association between moderate-to-severe OSA and incident diabetes over a 4-year follow-up period, but the sample size was small. In another study [59], OSA was independently associated with diabetes after adjusting for confounders [including BMI (body mass index)] over a mean follow-up period of 2.7 years. Interestingly, one clinic-based study of 168 middle-aged patients [60], reported a significantly higher incidence of diabetes in women

with OSA, but not in men with OSA, after a follow-up period of 16 years. In a prospective study of 4000 middle-aged adults, intermittent hypoxia was associated with an increased risk of developing diabetes after a 3-year median follow-up [61]. There is evidence from clinical studies to suggest that the presence and severity of OSA is associated with poor glucose control in diabetic patients [62].

One key question is whether CPAP therapy in patients with OSA improves glucose control in patients with diabetes. Five uncontrolled studies have examined the effects of CPAP on glycaemic control [63–67]. Two studies reported improvements in night-time glucose levels after 1 night [67] and 5 weeks [66] of CPAP use. Two other studies showed improved insulin sensitivity without a change in HbA_{1c} levels after 3–4 months of CPAP use [63,64]. In one study involving 25 obese patients with diabetes [65], there was a significant improvement in HbA_{1c} and post-prandial glucose levels after 3 months of CPAP therapy. One observational study found that patients with moderate-to-severe OSA who used CPAP regularly had a significant reduction in the rate of diabetes, even after adjusting for weight changes [59].

A total of eight studies using either parallel or cross-over randomized controlled designs have investigated the effects of CPAP therapy on measures of glucose metabolism; characteristics and main findings of these studies are shown in Table 1. Overall, only two of the eight studies [68,71] reported positive findings during the randomized treatment period, and another [72] had positive findings only in the open non-randomized extended portion of CPAP therapy. In the only randomized controlled study conducted in diabetic patients [70], 3 months of CPAP use had no effect on insulin sensitivity or HbA_{1c} (glycated haemoglobin) levels. Notably, use of CPAP was low, averaging about 3.3 h per night. Overall, the nightly treatment use (CPAP or sham-CPAP) was 5 h or less in most studies [70–74], which represents an important limitation of these randomized trials.

In summary, current evidence strongly supports an association between OSA and diabetes with a substantial proportion of patients with diabetes suffering from unrecognized OSA. Whether OSA represents an independent risk for the development of diabetes needs to be investigated further in large prospective studies. The role of OSA in the management of diabetes is in urgent need of further assessment, and there remains debate about whether CPAP treatment of OSA leads to improved glucose metabolism. Large scale randomized controlled trials of CPAP treatment of OSA with robust assessments of insulin sensitivity and glucose tolerance are needed.

CARDIOVASCULAR BIOMARKERS IN OSA

As described above, animals exposed to intermittent hypoxia suffer adverse cardiometabolic effects, including hypertension, dyslipidaemia, endothelial dysfunction and atherosclerosis. In observational studies, patients with OSA have a 3-fold increased risk of incident CVD (cardiovascular disease), including stroke and myocardial infarction [75]. However, there is currently a lack of definitive data regarding the benefits of CPAP for measurable cardiovascular outcomes such as stroke and myocardial infarction [76]. Long-term randomized controlled trials using such end points are challenging to perform in patients

with OSA for many reasons [77]. One issue is that it is both difficult and unethical to enrol sleepy patients into a prolonged study in which no therapy is provided to one of the groups, since patients would be denied symptomatic benefit as a result of the study design. In addition, the enrolment of asymptomatic patients may be problematic, since such patients may be poorly adherent with CPAP therapy due to lack of perceived benefits [78]. To complicate matters further, some data suggest that sleepy patients with OSA may be the ones more likely to experience cardiovascular benefits with CPAP treatment [79].

Consequently, many investigators have suggested that biomarkers could potentially be used as surrogate outcome measures to test the impact of sleep apnoea therapies [76,80,81]. A useful biomarker should be easy to measure, be consistently and strongly associated with future cardiovascular risk (preferably on the causal pathway), plausible and potentially show signs of improvement with treatment within a reasonably short time period [82].

One potentially useful biomarker would be BP (blood pressure) [83]. OSA is linked to the development of systemic hypertension based on animal studies of intermittent hypoxia for 24 h and also prospective epidemiological studies [2,84–86]. In addition, BP is easy to measure, and a consistent and well-recognized strong risk factor for the development of CVD [87].

However, the degree to which daytime BP is reduced after CPAP therapy is very modest (i.e. 2–3 mmHg) [88] and far less than that of antihypertensive medical therapy [89]. Before BP is dismissed as being unhelpful in the OSA biomarker arena, several points are worth considering. It is clear that OSA causes marked nocturnal surges in BP, which could be an important risk factor in plaque rupture [90]. These nocturnal BP surges are typically not captured by studies of daytime BP and thus the magnitude of the therapeutic benefits may be underestimated. In addition, some patients, such as those of younger age, sleepiness and increased CPAP adherence, may experience substantial BP reductions with OSA therapy [91–93]. Autoregulatory mechanisms maintain BP within a relatively narrow range [94]. Although speculative, reductions in catecholamines due to OSA treatment might thus have only a modest effect on BP due to these counter-regulatory mechanisms (e.g. baroreflexes and autoregulation), but the cardiovascular effects might be more substantial. Thus, although BP might be useful, other markers should also be looked at.

Inflammatory markers may also be useful biomarkers to consider. Many investigators accept CRP (C-reactive protein) as a marker of systemic inflammation and its regulation is thought to be IL (interleukin)-6-dependent. The JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study showed robust improvements in cardiovascular outcomes in patients with elevated CRP treated with rosuvastatin [95,96]. Hypoxaemia in sleep apnoea is thought to increase CRP levels. Several OSA studies have shown associations between OSA and CRP; however, these data are controversial since obesity is a dominant predictor of CRP in some studies. Interventional studies have also shown improvements in CRP with apnoea therapy [97], although these findings are not consistent across studies. However, the marked variability in the results with CPAP intervention suggests that CRP may be relatively insensitive to the burden of OSA. In addition, CRP may be predominantly a marker of CVD, rather than causally linked [98].

CMR (cardiac magnetic resonance) imaging is being increasingly used to assess cardiac structure and function [99]. Preliminary data support the use of CMR markers in studying the impact of OSA severity and treatment [100,101]. CMR imaging may thus provide a useful surrogate outcome measure which could be used in OSA clinical trials. A major issue is that testing is expensive, which may preclude use in large multi-centre trials.

CIMT (carotid intima media thickness), as assessed with carotid ultrasonography, may also be a marker to consider. CIMT is a marker of future atherosclerosis (atherosclerosis precursor) [102], and patients with increased CIMT (or changes in CIMT) are at increased risk of future cardiovascular events [103–105]. OSA appears to be associated with increased CIMT in a number of studies and is related to disease severity even after controlling for confounders [106,107]. A small randomized trial reported that that CPAP treatment of OSA reduced CIMT [108].

Clinical trials in OSA are limited by the lack of adequate biomarkers to use as surrogate outcome measures. Defining important markers, which can change in the shorter term, is a priority. Changes in biomarkers that provide compelling evidence for improved cardiovascular risk can be assessed in future controlled clinical trials using more robust clinical end points.

CONCLUSIONS

OSA is a common under-recognized disease. Accumulating data from both animals and humans implicate OSA as an important risk factor for cardiometabolic disease (see Figure 1). Future mechanistic studies using animal models, and human observational and intervention studies using biomarkers and robust clinical end points should provide more insights into the link between cardiometabolic health and sleep apnoea.

Acknowledgments

FUNDING

Our own work was supported by the National Institutes of Health [grant numbers R01-HL-075079 (to E.T.), program project grant P01-AG11412 (to E.T., project leader), CTSA-UL1 TR000430 (awarded to the University of Chicago), and R01 HL080105 (to V.Y.P.)], the Canadian Institutes for Health Research [Sleep Team grant (to N.T.A., A.A.J.H. and I.L.)], a Vancouver Coastal Health Research Institute Clinician Scientist award (to N.T.), a Canadian Institutes of Health Research Operating Grant [grant number MOP-82731] and the Clifford Nordal Chair in Sleep Apnea and Rehabilitation Research (to T.D.B.)

Abbreviations

AHI	apnoea/hypopnoea index
BP	blood pressure
CIMT	carotid intima media thickness
CMR	cardiac magnetic resonance
CPAP	continuous positive airway pressure
CRP	C-reactive protein

CVD	cardiovascular disease
HbA_{1c}	glycated haemoglobin
HIF	hypoxia-inducible factor
NZO	New Zealand obese
OSA	obstructive sleep apnoea

References

1. White DP. Sleep-related breathing disorder. 2. Pathophysiology of obstructive sleep apnoea. *Thorax*. 1995; 50:797–804. [PubMed: 7570420]
2. Epstein L, Weiss W. Clinical consequences of obstructive sleep apnea. *Semin Respir Crit Care Med*. 1998; 19:123–132.
3. Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. *Circulation*. 2011; 122:352–360. [PubMed: 20625114]
4. White LH, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. *J Physiol*. 2013; 591:1179–1193. [PubMed: 23230237]
5. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl Physiol*. 2005; 99:1592–1599. [PubMed: 16160020]
6. Peppard P, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol*. 2013; 177:1006–1014. [PubMed: 23589584]
7. Peppard P, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA*. 2000; 284:3015–3021. [PubMed: 11122588]
8. American Academy of Sleep Medicine Task Force. Sleep related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in adults. *Sleep*. 1999; 22:667–689. [PubMed: 10450601]
9. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*. 1993; 328:1230–1235. [PubMed: 8464434]
10. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. *Sleep*. 1997; 20:705–706. [PubMed: 9406321]
11. Malhotra A, Ayas N, Epstein L. The art and science of continuous positive airway pressure therapy in obstructive sleep apnea. *Curr Opin Pulm Med*. 2000; 6:490–495. [PubMed: 11100958]
12. Kribbs NB, Pack AI, Kline LR, Smith PL, Getsy JE, Schuett JS, Henry JN, Maislin G, Dinges DF. Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea. *Am Rev Respir Dis*. 1993; 147:1162–1168. [PubMed: 8484626]
13. Weaver TE, Maislin G, Dinges DF, Bloxham ST, George CF, Greenberg H, Kader G, Mahowald M, Younger J, Pack AI. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. *Sleep*. 2007; 30:711–719. [PubMed: 17580592]
14. Hendricks JC, Kline LR, Kovalski RJ, O'Brien JA, Morrison AR, Pack AI. The English bulldog: a natural model of sleep-disordered breathing. *J Appl Physiol*. 1987; 63:1344–1350. [PubMed: 3693167]
15. Hendricks JC, Kovalski RJ, Kline LR. Phasic respiratory muscle patterns and sleep-disordered breathing during rapid eye movement sleep in the English bulldog. *Am Rev Respir Dis*. 1991; 144:1112–1120. [PubMed: 1952441]
16. Schotland HM, Insko EK, Panckeri KA, Leigh JS, Pack AI, Hendricks JC. Quantitative magnetic resonance imaging of upper airways musculature in an animal model of sleep apnea. *J Appl Physiol*. 1996; 81:1339–1346. [PubMed: 8889772]

17. Petrof BJ, Pack AI, Kelly AM, Eby J, Hendricks JC. Pharyngeal myopathy of loaded upper airway in dogs with sleep apnea. *J Appl Physiol.* 1994; 76:1746–1752. [PubMed: 8045855]
18. Reference deleted
19. Veasey SC, Fenik P, Panckeri K, Pack AI, Hendricks JC. The effects of trazodone with L-tryptophan on sleep-disordered breathing in the English bulldog. *Am J Respir Crit Care Med.* 1999; 160:1659–1667. [PubMed: 10556137]
20. Veasey SC, Chachkes CJ, Fenik P, Hendricks JC. The effects of ondansetron on sleep-disordered breathing in the English bulldog. *Sleep.* 2001; 24:155–160. [PubMed: 11247051]
21. Crossland RF, Durgan DJ, Lloyd EE, Phillips SC, Reddy AK, Marrelli SP, Bryan RM Jr. A new rodent model for obstructive sleep apnea: effects on ATP-mediated dilations in cerebral arteries. *Am J Physiol Regul Integr Comp Physiol.* 2013; 305:R334–R342. [PubMed: 23761641]
22. Brennick MJ, Pack AI, Ko K, Kim E, Pickup S, Maislin G, Schwab RJ. Altered upper airway and soft tissue structures in the New Zealand Obese mouse. *Am J Respir Crit Care Med.* 2009; 179:158–169. [PubMed: 18996996]
23. Schwab RJ, Gupta KB, Geffer WB, Metzger LJ, Hoffman EA, Pack AI. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. *Am J Respir Crit Care Med.* 1995; 152:1673–1689. [PubMed: 7582313]
24. Schwab RJ, Pack AI, Gupta KB, Metzger LJ, Oh E, Getsy JE, Hoffman EA, Geffer WB. Upper airway and soft tissue structural changes induced by CPAP in normal subjects. *Am J Respir Crit Care Med.* 1996; 154:1106–1116. [PubMed: 8887615]
25. Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadoorian R, Arens R, Maislin G, Pack AI. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. *Am J Respir Crit Care Med.* 2003; 168:522–530. [PubMed: 12746251]
26. Polotsky M, Elsayed-Ahmed AS, Pichard L, Harris CC, Smith PL, Schneider H, Kirkness JP, Polotsky V, Schwartz AR. Effects of leptin and obesity on the upper airway function. *J Appl Physiol.* 2012; 112:1637–1643. [PubMed: 22345430]
27. Chen L, Scharf SM. Effects of aortic nerve on hemodynamic response to obstructive apnea in sedated pigs. *J Appl Physiol.* 2000; 89:1455–1461. [PubMed: 11007582]
28. Nacher M, Serrano-Mollar A, Farre R, Panes J, Segui J, Montserrat JM. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. *Respir Physiol Neurobiol.* 2007; 155:93–96. [PubMed: 17027348]
29. Neuzeret PC, Gormand F, Reix P, Parrot S, Sastre JP, Buda C, Guidon GK, Sakai K, Lin JS. A new animal model of obstructive sleep apnea responding to continuous positive airway pressure. *Sleep.* 2011; 34:541–548. [PubMed: 21461333]
30. Kimoff RJ, Makino H, Horner RL, Kozar LF, Lue F, Slutsky AS, Phillipson EA. Canine model of obstructive sleep apnea: model description and preliminary application. *J Appl Physiol.* 1994; 76:1810–1817. [PubMed: 8045863]
31. Horner RL, Brooks D, Kozar LF, Leung E, Hamrahi H, Render-Teixeira CL, Makino H, Kimoff RJ, Phillipson EA. Sleep architecture in a canine model of obstructive sleep apnea. *Sleep.* 1998; 21:847–858. [PubMed: 9871947]
32. Hamrahi H, Stephenson R, Mahamed S, Liao KS, Horner RL. Regulation of sleep-wake states in response to intermittent hypoxic stimuli applied only in sleep. *J Appl Physiol.* 2001; 90:2490–2501. [PubMed: 11356818]
33. Veasey S. Insight from animal models into the cognitive consequences of adult sleep-disordered breathing. *ILAR J.* 2009; 50:307–311. [PubMed: 19506315]
34. Polotsky VY, Rubin AE, Balbir A, Dean T, Smith PL, Schwartz AR, O'Donnell CP. Intermittent hypoxia causes REM sleep deficits and decreases EEG delta power in NREM sleep in the C57BL/6J mouse. *Sleep Med.* 2006; 7:7–16. [PubMed: 16309961]
35. Lee EJ, Woodske ME, Zou B, O'Donnell CP. Dynamic arterial blood gas analysis in conscious, unrestrained C57BL/6J mice during exposure to intermittent hypoxia. *J Appl Physiol.* 2009; 107:290–294. [PubMed: 19056995]

36. Reinke C, Bevans-Fonti S, Drager LF, Shin MK, Polotsky VY. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. *J Appl Physiol.* 2011; 111:881–890. [PubMed: 21737828]
37. Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, Polotsky VY. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. *Obesity.* 2011; 19:2167–2174. [PubMed: 21799478]
38. Fletcher EC. Physiological consequences of intermittent hypoxia: systemic blood pressure. *J Appl Physiol.* 2001; 90:1600–1605. [PubMed: 11247966]
39. Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O'Donnell CP, Polotsky VY. Intermittent hypoxia induces hyperlipidemia in lean mice. *Circ Res.* 2005; 97:698–706. [PubMed: 16123334]
40. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. Chronic intermittent hypoxia induces atherosclerosis. *Am J Respir Crit Care Med.* 2007; 175:1290–1297. [PubMed: 17332479]
41. Fletcher EC, Bao G, Miller MCC III. Effect of recurrent episodic hypocapnic, eucapnic, and hypercapnic hypoxia on systemic blood pressure. *J Appl Physiol.* 1995; 78:1516–1521. [PubMed: 7615464]
42. Fletcher, EC.; Bao, G. Influence of hypoxia, chemoreceptors, and sympathetic activity in chronic hypertension in the rat. In: Lenfant, C.; Bradley, TD.; Floras, JS., editors. *Sleep Apnea: Implications in Cardiovascular and Cerebrovascular Disease.* Marcel Dekker; New York: 2000. p. 181–211.
43. Prabhakar NR, Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. *Physiol Rev.* 2012; 92:967–1003. [PubMed: 22811423]
44. Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, Polotsky VY. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. *Obesity.* 2011; 19:2167–2174. [PubMed: 21799478]
45. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. *Proc Nutr Soc.* 2009; 68:370–377. [PubMed: 19698203]
46. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of *ob/ob* and dietary obese mice. *Am. J. Physiol. Endocrinol. Metab.* 2007; 293:E1118–E1128.
47. Lavie L. Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. *Front Biosci (Elite Ed).* 2012; 4:1391–1403. [PubMed: 22201964]
48. Kanagy NL. Vascular effects of intermittent hypoxia. *ILAR J.* 2009; 50:282–288. [PubMed: 19506314]
49. Williams AL, Chen L, Scharf SM. Effects of allopurinol on cardiac function and oxidant stress in chronic intermittent hypoxia. *Sleep Breath.* 2010; 14:51–57. [PubMed: 19603215]
50. Louis M, Punjabi NM. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. *J Appl Physiol.* 2009; 106:1538–1544. [PubMed: 19265062]
51. Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. *Proc Natl Acad Sci USA.* 2008a; 105:1044–1049. [PubMed: 18172212]
52. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. *Chest.* 2009; 137:95–101. [PubMed: 19542260]
53. Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and Type 2 diabetes: interacting epidemics. *Chest.* 2008; 133:496–506. [PubMed: 18252916]
54. Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. *Eur Respir J.* 2009; 34:243–260. [PubMed: 19567607]
55. Meslier N, Gagnadoux F, Giraud P, Person C, Oukel H, Urban T, Racineux JL. Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. *Eur Respir J.* 2003; 22:156–160. [PubMed: 12882466]
56. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. *Am J Respir Crit Care Med.* 2005; 172:1590–1595. [PubMed: 16192452]
57. Seicean S, Kirchner HL, Gottlieb DJ, Punjabi NM, Resnick H, Sanders M, Budhiraja R, Singer M, Redline S. Sleep disordered breathing and impaired glucose metabolism in normal weight and

- overweight/obese individuals: The Sleep Heart Health Study. *Diabetes Care*. 2008; 31:1001–1006. [PubMed: 18268072]
58. Marshall NS, Wong KK, Phillips CL, Liu PY, Knuiman MW, Grunstein RR. Is sleep apnea an independent risk factor for prevalent and incident diabetes in the Busselton Health Study? *J Clin Sleep Med*. 2009; 5:15–20. [PubMed: 19317376]
  59. Botros N, Concato J, Mohsenin V, Selim B, Doctor K, Yaggi HK. Obstructive sleep apnea as a risk factor for type 2 diabetes. *Am J Med*. 2009; 122:1122–1127. [PubMed: 19958890]
  60. Celen YT, Hedner J, Carlson J, Peker Y. Impact of gender on incident diabetes mellitus in obstructive sleep apnea: a 16-year follow-up. *J Clin Sleep Med*. 2010; 6:244–250. [PubMed: 20572417]
  61. Muraki I, Tanigawa T, Yamagishi K, Sakurai S, Ohira T, Imano H, Kitamura A, Kiyama M, Sato S, Shimamoto T, et al. Nocturnal intermittent hypoxia and the development of type 2 diabetes: the Circulatory Risk in Communities Study (CIRCS). *Diabetologia*. 2010; 53:481–488. [PubMed: 19946661]
  62. Pillai A, Warren G, Gunathilake W, Idris I. Effects of sleep apnea severity on glycemic control in patients with type 2 diabetes prior to continuous positive airway pressure treatment. *Diabetes Technol Ther*. 2011; 13:945–949. [PubMed: 21714680]
  63. Brooks B, Cistulli PA, Borkman M, Ross G, Mcghee S, Grunstein RR, Sullivan CE, Yue DK. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. *J Clin Endocrinol Metab*. 1994; 79:1681–1685. [PubMed: 7989475]
  64. Harsch IA, Schahin SP, Bruckner K, Radespiel-Troger M, Fuchs FS, Hahn EG, Konturek PC, Lohmann T, Ficker JH. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. *Respiration*. 2004; 71:252–259. [PubMed: 15133345]
  65. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. *Arch Intern Med*. 2005; 165:447–452. [PubMed: 15738376]
  66. Dawson A, Abel SL, Loving RT, Dailey G, Shadan FF, Cronin JW, Kripke DF, Kline LE. CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. *J Clin Sleep Med*. 2008; 4:538–542. [PubMed: 19110882]
  67. Pallayova M, Donic V, Tomori Z. Beneficial effects of severe sleep apnea therapy on nocturnal glucose control in persons with type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2008; 81:e8–e11. [PubMed: 18440086]
  68. Lam JC, Lam B, Yao TJ, Lai AY, Ooi CG, Tam S, Lam KS, Ip MS. A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. *Eur Respir J*. 2010; 35:138–145. [PubMed: 19608589]
  69. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese men with OSA. *Eur Respir J*. 2007; 29:720–727. [PubMed: 17251237]
  70. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. *Thorax*. 2007; 62:969–974. [PubMed: 17557769]
  71. Weinstock TG, Wang X, Rueschman M, Ismail-Beigi F, Aylor J, Babineau DC, Mehra R, Redline S. A controlled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea. *Sleep*. 2012; 35:617–625. [PubMed: 22547887]
  72. Hoyos CM, Killick R, Yee BJ, Phillips CL, Grunstein RR, Liu PY. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study. *Thorax*. 2012; 67:1081–1089. [PubMed: 22561530]
  73. Nguyen PK, Katikireddy CK, McConnell MV, Kushida C, Yang PC. Nasal continuous positive airway pressure improves myocardial perfusion reserve and endothelial-dependent vasodilation in patients with obstructive sleep apnea. *J Cardiovasc Magn Reson*. 2010; 12:50. [PubMed: 20815898]

74. Sivam S, Phillips CL, Trenell MI, Yee BJ, Liu PY, Wong KK, Grunstein RR. Effects of 8 weeks of CPAP on abdominal adiposity in obstructive sleep apnoea. *Eur Respir J*. 2012; 40:913–918. [PubMed: 22267762]
75. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet*. 2005; 365:1046–1053. [PubMed: 15781100]
76. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med*. 2005; 353:2034–2041. [PubMed: 16282178]
77. Malhotra A, Loscalzo J. Sleep and cardiovascular disease: an overview. *Prog Cardiovasc Dis*. 2009; 51:279–284. [PubMed: 19110129]
78. Craig SE, Kohler M, Nicoll D, Bratton DJ, Nunn A, Davies R, Stradling J. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. *Thorax*. 2012; 67:1090–1096. [PubMed: 23111478]
79. Montesi SB, Bajwa EK, Malhotra A. Biomarkers of sleep apnea. *Chest*. 2012; 142:239–245. [PubMed: 22796846]
80. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. *Ann Intern Med*. 2005; 142:187–189. [PubMed: 15684207]
81. Caples SM, Garcia-Touchard A, Somers VK. Sleep-disordered breathing and cardiovascular risk. *Sleep*. 2007; 30:291–303. [PubMed: 17425225]
82. Aronson JK. Biomarkers and surrogate endpoints. *Br J Clin Pharm*. 2005; 59:491–494.
83. Martínez-García M, Capote F, Campos-Rodríguez F, Lloberes P, Diaz de Atauri MJ, Samozá M, Masa JF, Montserrat JM. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. *JAMA*. 2013; 310:2407–2415. [PubMed: 24327037]
84. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnea syndrome as a risk factor for hypertension. *BMJ*. 2000; 320:479–482. [PubMed: 10678860]
85. Nieto F, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA*. 2000; 283:1829–1836. [PubMed: 10770144]
86. Pepperell J, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling J, Davies RJO. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. *Lancet*. 2002; 359:204–210. [PubMed: 11812555]
87. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. *Am J Respir Crit Care Med*. 2005; 172:1447–1451. [PubMed: 16141444]
88. Montesi S, Edwards BA, Malhotra A, Bakker J. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. *J Clin Sleep Med*. 2012; 8:587–596. [PubMed: 23066375]
89. Pepin JL, Tamisier R, Barone-Rochette G, Launois SH, Levy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. *Am J Respir Crit Care Med*. 2010; 182:954–960. [PubMed: 20522795]
90. Stradling J, Davies RJ. Sleep apnea and hypertension – what a mess! *Sleep*. 1997; 20:789–793. [PubMed: 9406330]
91. Becker H, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan C, Peter JH. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. *Circulation*. 2003; 107:68–73. [PubMed: 12515745]
92. Logan AG, Tkacova R, Perlikowski SM, Leung RS, Tisler A, Floras JS, Bradley TD. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. *Eur Respir J*. 2003; 21:241–247. [PubMed: 12608436]
93. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. *Prog Cardiovasc Dis*. 2009; 51:371–380. [PubMed: 19249443]

94. Guyenet PG. The sympathetic control of blood pressure. *Nat Rev Neurosci.* 2006; 7:335–346. [PubMed: 16760914]
95. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med.* 2001; 344:1959–1965. [PubMed: 11430324]
96. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med.* 2008; 359:2195–2207. [PubMed: 18997196]
97. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. *Circulation.* 2003; 107:1129–1134. [PubMed: 12615790]
98. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Smith GD. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. *Lancet.* 2005; 366:1954–1959. [PubMed: 16325697]
99. Mousavi N, Czarnecki A, Kumar K, Fallah-Rad N, Lytwyn M, Han SY, Jassal DS. Relation of biomarkers and cardiac magnetic resonance imaging after marathon running. *Am J Cardiol.* 2009; 103:1467–1472. [PubMed: 19427448]
100. Bakker JP, Sharma B, Malhotra A. Obstructive sleep apnea: the elephant in the cardiovascular room. *Chest.* 2012; 141:580–581. [PubMed: 22396556]
101. Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M, Jassal DS. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. *Chest.* 2012; 141:674–681. [PubMed: 21835901]
102. Mancini GBJ, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. *Circulation.* 2004; 109 (Suppl):22–30.
103. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. *Am J Epidemiol.* 1997; 146:483–494. [PubMed: 9290509]
104. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. *Ann Intern Med.* 1996; 124:548–556. [PubMed: 8597317]
105. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. *Circulation.* 2002; 106:2055–2060. [PubMed: 12379573]
106. Silvestrini M, Rizzato B, Placidi F, Baruffaldi R, Bianconi A, Diomedes M. Carotid artery wall thickness in patients with obstructive sleep apnea syndrome. *Stroke.* 2002; 33:1782–1785. [PubMed: 12105352]
107. Suzuki T, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Yamauchi M, Kimura H. Obstructive sleep apnea and carotid-artery intima-media thickness. *Sleep.* 2004; 27:129–133. [PubMed: 14998249]
108. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit Care Med.* 2007; 176:706–712. [PubMed: 17556718]
109. Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Crosthwaite N, Craig S, Siccoli MM, Davies RJ, Stradling JR. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. *Thorax.* 2009; 64:67–73. [PubMed: 18786982]

Figure 1. OSA as an important risk factor for cardiometabolic disease
TIA, transient ischaemic attack.

Table 1

Randomized controlled studies examining the effects of CPAP treatment of OSA on glucose metabolism

Author (year)	Number of patients	Duration of study	Main findings
Coughlin et al. (2007) [69]	17 (CPAP/sham) 17 (sham/CPAP)	6 weeks	No difference in insulin sensitivity or fasting glucose and insulin
West et al. (2007) [70]	20 Type 2 diabetics (CPAP/sham) 22 Type 2 diabetics (sham/CPAP)	3 months	No difference in insulin sensitivity or HbA _{1c}
Lam et al. (2010) [68]	31 (CPAP) 30 (sham)	1 week	Improvement in insulin sensitivity at 1 week
Nguyen et al. (2010) [73]	10 (CPAP) 10 (sham CPAP)	3 months	No difference in fasting glucose
Kohler et al. (2009) [109]	20 (CPAP) 20 (CPAP withdrawal)	2 weeks	No difference in insulin sensitivity
Hoyos et al. (2012) [72]	34 (CPAP) 31 (sham)	12 weeks	No difference in insulin sensitivity at 12 weeks
Sivam et al. (2012) [74]	27 (CPAP/sham or sham/CPAP)	8 weeks	No difference in fasting glucose
Weinstock et al. (2012) [71]	25 Pre-diabetics (CPAP/sham) 25 Pre-diabetics (sham/CPAP)	8 weeks	No difference in HOMA or 2 h glucose; improvement in insulin sensitivity and 2 h insulin only in severe OSA

HOMA, homoeostatic model assessment.